Fig.3From: CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitroImmune stimulation of trastuzumab treated HER2 + breast cancer cells. Normalized percent change in confluence of a BT474, b SKBR3 and c MDA-MB-453 and d MDA-MB-231 breast cancer cells in response to 25 µg/mL trastuzumab and CD4 + T-cell presence. Significant differences in cell viability between (1) trastuzumab treated cancer cells and (2) trastuzumab treated co-cultured cells was only observed in BT474 and SKBR3 cells (p = 0.01). Decreased cell viability between (1) trastuzumab treated cancer cells and (2) trastuzumab treated co-cultured cells was only observed in MDA-MB-453 cells was observed but was only trending toward significance (p = 0.08). Error bars are representative of standard error of mean (SEM)Back to article page